Acute coronary syndrome (ACS) has become a vital disease with high mortality worldwide. A combined antiplatelet therapy (aspirin and a P2Y 12 antagonist) is commonly used to prevent re-infarction in ACS patients who have undergone percutaneous coronary intervention (PCI). Clopidogrel, a P2Y 12 antagonist, plays an important role in the inhibition of platelet aggregation (IPA). However, it is a pro-drug requiring biotransformation by cytochrome P450 (CYP450). The aim of this study is to unravel the effect of clopidogrel-associated genetic variants on inhibition of platelet activity and clinical outcomes in ACS patients. In our study, a total of 196 patients with metabolic gene polymorphism of clopidogrel were enrolled, and their antiplatelet effect as well as their cardiovascular events were collected. Approximately 2 mL of venous blood samples were used for genotype detection and another 4 mL were collected for platelet reactivity with thrombelastography. The primary clinical end-point was defined as a combination of cardiovascular mortality and revascularization for targeted vascular lesion. Based on the results of IPA, the prevalence of high on-treatment platelet reactivity (HPR) was 17.3% and the majority of patients (82.7%) obtained normal on-treatment platelet reactivity (NPR). The HPR group had significantly higher body mass index (BMI) and lower arachidonic acid (AA) induced IPA (P < 0.05). Therapy including Glycoprotein (GP) IIb/IIIa antagonist increased IPA (P < 0.05). ADP-induced IPA effect was lower with the presence of CYP2C19*2, *3 and paraoxonase (PON)1 Q192R loss-of-function (LOF) alleles, respectively (P < 0.05). Multivariate logistic regression analysis demonstrated that aspirin resistance (AA-induced IPA < 50%) had a greater risk of the occurrence of major adverse cardiovascular events (MACE) (OR = 3.817; 95% CI: 1.672-8.700; P = 0.002). CYP2C19*2 LOF alleles were associated with high risk of MACE in 1-year post PCI operations (OR = 2.571; 95% CI: 1.143-5.780; P = 0.030). For the ACS patients, the presence of CYP2C19*2 and PON1 Q192R LOF alleles were the major drivers of HPR.
| INTRODUCTION
Coronary atherosclerosis is a major cause of coronary heart disease (CHD). The common risk factors contributing to the development of CHD are advanced age, smoking, obesity, hypertension, high cholesterol and diabetes, etc. 1 In the case of coronary atherosclerosis, lipids drive inflammation on the endothelium and accelerate plaque formation on vulnerable coronaries. 2 Generally, patients with background of coronary atherosclerosis are more likely to develop acute coronary syndrome (ACS): the decreased blood flow as well as the platelet aggregation on the thrombogenic trigger point when plaque ruptures might contribute to the occurrence of ACS. 3, 4 According to an epidemiologic report in 2015, approximately 230 million people were affected by cardiovascular heart disease in China. 5 As suggested by the clinical practice guidelines from the European Society of Cardiology (ESC), 3 dual antiplatelet therapy could prevent the re-infarction in ACS patients who have undergone percutaneous coronary intervention (PCI). Clopidogrel is the most widely used P2Y 12 receptor antagonist irreversibly inhibiting adenosine diphosphate (ADP) binding to its receptor 6 and it plays an important role in the inhibition of platelet aggregation (IPA). 7 Clopidogrel transforms into its active metabolites under the catalysation of cytochrome P450 (CYP). 8 Many articles have reported that the presence of reduced-function of CYP2C19 allele (particular *2/*2, *2/*3, *3/*3) might be associated with an increased risk of stent thrombosis and major adverse cardiovascular events (MACE). [9] [10] [11] CYP2C19-related decrease in drug metabolism has been proven to slow down the antiplatelet activity in ACS patients who have received a loading dose of clopidogrel. 12 Studies have reported that the nonresponse rate of clopidogrel of CYP2C19 loss-of-function (LOF) alleles ranged from 5% to 44%. 13 Evidence has shown that efflux pump P-glycoprotein (P-gp) transporting drugs across extra-and intracellular membrane encoded by ABCB1 may contribute to variability in clopidogrel response by affecting absorption. 14 As shown in Figure 1 , CYP2C19, ABCB1 and paraoxonase (PON1) are mainly involved in the metabolic pathway of clopidogrel. Therefore, we hypothesized that ACS patients prescribed with clopidogrel would have different responses to the antiplatelet effect of clopidogrel because of individual genetic variants. In addition, most clinical studies on clopidogrel relevant genetic variants have been based on Caucasians so far, and we are lack of data based on Asians (specifically Chinese ethnic group). Since the living habits as well as the dietary habits differ a lot, the results based on patients from China might provide additional information and to understand clopidogrel relevant genetic variants.
In our study, the genotype of CYP2C19 (*2, *3, *17), PON-1 and P-glycoprotein transport gene (ABCB-1) were determined from each ACS patient's blood and the response to clopidogrel was also recorded. We aimed to investigate the association of clopidogrel-related metabolic gene polymorphism with its clinical antiplatelet effect in ACS patients. 
| Patients' information
This single, prospective cohort study enrolled 219 patients who were diagnosed with ACS according to the ESC guideline 4 in the Department of Cardiac Intensive Care Unit of Zhongshan Hospital at Fudan University from January 2016 to December 2016. All the patients presented with symptoms of chest pain, discomfort, shortness of breath, dizziness, nausea and sweat. Cardiac biomarkers including troponin and creatine kinase were elevated, and the electrocardiogram (ECG) showed a change in T wave and ST segment. PCI operations were carried out for all enrolled patients in the cardiac catheterization surgery. A 300-mg loading dose (LD) of clopidogrel was administered before PCI operation followed by a maintenance dose (MD) of 75 mg/d. In addition, all enrolled patients were medicated with concomitant drugs including aspirin (LD/MD: 300 mg/ 100 mg), low-molecular-weight heparin, renin-angiotensinaldosterone system antagonists, statins and beta blockers when admitted to the hospital. All drugs were administered as single doses by nurses and pharmacists. All ACS patients enrolled were implanted with a drugeluting stent (DES) on the occlusion coronary. After PCI operation, the patients were medicated with clopidogrel for at least one year, and follow-up appointments were scheduled every month after discharge and done via telephone and outpatient clinic visits. Among all enrolled patients, 23 patients were lost to follow-up and the final study sample size was 196 with a total loss rate of 10.6%.
This study was conducted in compliance with the Helsinki Declaration and Good Clinical Practice and was approved by the Ethics Committee of Zhongshan Hospital. A written informed consent was signed by all participants before the clinical studies commenced.
As described above, all patients involved were scheduled for a PCI operation and met the following eligibility criteria: (a) age ≥18 years; (b) receiving dual antiplatelet therapy including aspirin and clopidogrel; (c) presence of chest pain ≥10 minutes, change of ST segment and T wave of ECG and elevation of cardiac biomarkers. The main exclusion criteria included the following: (a) history of bleeding and haemorrhagic disease; (b) allergy to clopidogrel and aspirin; (c) severe hepatic or renal dysfunction; (d) New York Heart Association (NYHA) grade IV heart failure.
| Blood sample collection
Approximately 2 mL of whole venous blood samples for genotyping were collected into a vacutainer containing anticoagulant Ethylene Diamine Tetra-acetic Acid (EDTA) from patients upon recruitment. About 4 mL of whole peripheral blood samples were collected after patients had received LD clopidogrel to detect the on-treatment platelet reactivity with thrombelastography (TEG; Haemoscope Corp, Niles, IL, USA).
| Genotyping
The DNA of each patient was isolated by using the QIAamp DNA Blood Kit (Qiagen, Hilden, Germany) and the single nucleotide polymorphisms (SNPs) of the CYP2C19 phenotype were determined by the DNA assay method. Loss-of-function alleles of CYP2C19*2, *3, *17, ABCB1 and PON1-192R gene variant were the point mutation of 681G>A (rs4244285), 636 G>A (rs4986893), 806 C>T (rs12248560), 3435 C>T (rs1045642) and 575 A>G (rs662), respectively. 15 Ultra-metabolizers were defined as the combination of alleles (*1/*17) and (*17/*17). 16 The extensive metabolizers (EM) were defined as the combination of alleles (*1/ *1), intermediated metabolizers (IM) were defined as the combination of alleles (*1/*2) and (*1/*3) and poor metabolizers (PM) were defined as the combination of alleles (*2/*2), (*2/*3) and (*3/*3). 17 
| Antiplatelet measurements
After 5 days of LD clopidogrel administration, ADPinduced IPA was measured by TEG, based on the principle of blood coagulation. The mechanical electrical transducer was used to test the status of clot in whole blood. The changes of amplitude were recorded by a computer during the thrombosis process. 18 The largest change in the value of the amplitude of coagulation intensity was defined as the maximum clot strength (MA). The MA was classified into the thrombin-induced maximum coagulation strength (MA thrombin ), the 20 μmol/L ADP-induced maximum coagulation strength (MA ADP ) and the fibrin-induced maximum coagulation strength (MA Fibrin ) according to different types of activators added to the blood sample. The ADP-induced IPA for clopidogrel was calculated by the formula: ADPinduced IPA (%) = (MA ADP − MA Fibrin )/(MA thrombin − MA Fibrin ). 19 According to a previous study, the relating IPA <30% induced by 20 μmol/L ADP was defined as clopidogrel high on-treatment platelet reactivity (HPR).
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Aspirin resistance is defined as the occurrence of more than 50% platelet aggregation after stimulation by 1 mmol/L AA as measured by TEG after aspirin therapy. 21 
| Clinical outcomes
Follow-ups were made mainly via outpatient interviews after discharge. Telephone interviews were done for the patients who lacked a medical record. The primary clinical end-point was MACE including cardiovascular death, cardiovascular mortality, myocardial infarction and revascularization for the targeted vascular lesion. 22 Thrombolysis in myocardial infarction (TIMI) bleeding was defined as bleeding events associated with decrease in haemoglobin or haematocrit values. 23 
| Sample size calculation and statistical analysis
According to a previously published study, 24 there was around 12% difference in 20-μmol ADP-induced IPA between carriers vs noncarriers of CYP2C19*2 LOF alleles. The prevalence of CYP2C19*2 LOF allele was approximately 26% for the Chinese population. At least about 164 patients were required to provide a power of 90% to detect a statistically significant difference with a two-side α-level of 0.05. Finally, a total of 196 patients were enrolled. All statistical analyses were performed with SPSS software (IBM SPSS Statistics 22.0, New York, NY, USA). The results with P values less than 0.05 (P < 0.05) were regarded as significant. The numerical data are presented as mean ± standard deviation. Comparisons between groups were performed with the two-tailed t test. Categorical variables were expressed with frequencies ± percentage and compared with chi-square test. The differences in distribution of genotype and allele prevalence of gene polymorphisms between groups were compared with chi-square test.
The cut-off value of ADP high sensitive test from TEG was considered to be 30%. Univariable and multivariable logistic regression analysis were applied to examine whether clopidogrel-associated gene variants were associated with clopidogrel resistance for ACS patients.
We analysed MACE using multiple statistical models. Variables including age, smoking status, hypertension, hyperlipidaemia, diabetes mellitus, previous PCI operation, left ventricular ejection fraction, IPA, and clopidogrel relevant gene variants were analysed. Hazard ratios (HRs) with two-sided 95% confidence intervals (CIs) were calculated for the risk factors of MACE. Results are presented as HRs along with 95% CI. Survival curves were constructed using Kaplan-Meier estimates. A two-sided P value was used to test for significance (threshold, P < 0.05) 3 | RESULTS
| Baseline characteristics
In our study, a total of 196 eligible Chinese-Han ACS patients were enrolled after screening. All enrolled patients completed a 1-year follow-up. The background characteristics of the patients are shown in Table 1 . Approximately 81.6% were males and the mean age was 64.4 ± 11.1 years. During the 1-year post PCI operation follow-up, 25 (12.7%) patients were re-hospitalized for revascularization, 3 (1.5%) patients had stroke and 8 (4.1%) patients had bleeding complications.
| Distribution of genotype and allele prevalence of gene polymorphisms
In our study, we genotyped all the five genetic variants including CYP2C19*2(rs4244285), *3(rs4986893), *17 (rs12248560), ABCB1 C3435T (rs1045642) and PON1 Q192R (rs662) that were associated with clinical effect of clopidogrel. Except for PON1 Q192R (rs662), all genetic variants of our study population were in Hardy-Weinberg equilibrium (P > 0.05). The minor allele frequency (MAF) of CYP2C19*3, PON1 Q192R in our study was higher than HapMap data (4.8% vs 3% and 48.5% vs 43%), whereas the MAF of CYP2C19*2, *17, ABCB1 C3435T was lower than HapMap data (20.9% vs 26%, 1.3% vs 2%, 37.2% vs 42%, respectively) ( Table 2) . We measured levels of IPA-induced by ADP for all patients. Significant differences were observed among the groups using one-way analysis of variance (Table 3) . Compared with CYP2C19 wild-type alleles, both CYP2C19*2 and *3 LOF alleles were associated with higher ADPinduced IPA (P < 0.001). Furthermore, a strong association was found between the PON1 genotypes and ADP-induced IPA (P < 0.001). ABCB1 and CYP2C19*17 showed no association with the rate of ADP-induced IPA (P > 0.05).
| Comparison of clinical characteristics
with clopidogrel HPR and normal ontreatment platelet reactivity
The cut-off value for the ADP-induced IPA was defined as ≥30% by TEG. On the basis of the results of IPA after 5 days of LD clopidogrel administration, the prevalence of clopidogrel HPR was 17.3% and the majority of patients (82.7%) obtained clopidogrel normal on-treatment platelet reactivity (NPR). The comparison of clinical characteristics between the two groups are shown in Table 4 . The HPR group had a significantly higher BMI index and a lower mean arachidonic acid (AA)-induced IPA, compared to the NPR group (P < 0.05). Moreover, medication with Glycoprotein (GP) IIb/IIIa receptor antagonist increased IPA (P < 0.05). ADP-induced IPA was lower with the presence of CYP2C19*2, *3, PON1 Q192R LOF alleles, respectively (P < 0.05). 
| The risk factors of MACE
During the 1-year follow-up, the primary MACE (major adverse cardiovascular events) included re-hospitalization for revascularization and stroke occurrence is 28 (14.2%).
In multivariate logistic regression analysis, aspirin resistance (AA-induced IPA < 50%) had a greater risk of occurrence of MACE (OR = 3.817; 95% CI: 1.672-8.700; P = 0.002). There was no significant difference between ADP-induced IPA and MACE (P = 0.106). CYP2C19*2 LOF alleles were associated with high risk of MACE in 1 year after PCI (OR = 2.571; 95% CI: 1.143-5.780; P = 0.030) ( Table 5 ). However, there was no significant difference between the other LOF alleles and MACE. Figure 2 shows the Kaplan-Meier curves for the cumulative rates of MACE in 1 year after PCI. The ratio of presence of CYP2C19*2 LOF alleles was higher in the MACE group (53.5%) than that in the non-MACE group (30.9%).
| DISCUSSION
ACS remains a life-threatening cardiovascular disease with high morbidity and mortality. 25 Due to the rupture of atherosclerotic plaques, activated platelets aggregate to form thrombosis. 26 Dual antiplatelet therapy (aspirin plus clopidogrel) could decrease the occurrence of MACE for ACS patients. 27 The active metabolite of clopidogrel could inhibit platelet activation and aggregation through competitive inhibition on ADP receptors. However, poor metabolizers could influence the pharmacokinetics of clopidogrel, resulting in inaccessible and impaired antiplatelet effect as well as reduced clinical effect. 28 Preliminary data demonstrated that genetic variants may influence the metabolism of clopidogrel, presumably leading to individual clinical effect of platelet inhibition. In our study, we refer to age, gender, smoking status and cardiovascular risk factors including hypertension, hyperlipidemia and diabetes as associated risk factors for occurrence of CHD. According to many recent estimates, growing age is an independent risk factor of cardiovascular disease primarily leading to compromised plasticity of vessels. 30 Smoking is another important risk factor mainly due to the reason that cigarette chemicals could cause coronary inflammation. 31 And indeed, in our study, 49.5% of the enrolled patients with a smoking history developed ACS. Further, almost half of our enrolled subjects had at least one of the cardiovascular risk factors. Excess pressure and vascular injury in coronary arteries resulted from these cardiovascular risk factors build up fat and cholesterol substances called plaque. This process finally results in atherosclerosis. 32 Many studies have provided evidence that the CYP2C19 LOF alleles cause poor IPA and increase the risk of stent thromboembolism. 15 It has been reported that the rate of CYP2C19*2 (681G>A, rs4244285) LOF alleles is 29%-35% in Asians, which is higher than that in Caucasians (15%). 33 The rate of CYP2C19*3 (636G>A rs4986893) LOF alleles is 5%-10% in East Asians, which is still higher than that of Caucasian populations. 15 In our study, the prevalence of CYP2C19*2 LOF alleles was higher than that in previous studies, but the prevalence of CYP2C19*3, CYP2C19*17, ABCB-C3435T and PON1 192R LOF alleles were all similar with a previous report.
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Of note, the distribution of PON1 192R (rs662) LOF alleles were markedly different from the previous report (48.5% vs 43% for MAF) mainly due to our study population.
The previous study demonstrated that significantly higher ADP-mediated aggregation values were found in patients with higher BMI (r = 0.14, P = 0.023). Therefore, BMI is emerged as an independent predictor for clopidogrel resistance [OR (95% CI), 1.45 (1.01-2.12), P = 0.049]. 34 demonstrated that higher BMI levels would be associated with higher platelet aggregation which is previous. The main reason might be that obesity contributes to endothelial dysfunction and inflammation in the vascular wall, resulting in elevated platelet activity. Platelet GP IIb/IIIa receptor blocker can inhibit formation of thromboembolism by preventing fibrinogen from binding to platelet IIb/IIIa receptors, which is the final pathway for platelet aggregation. Platelet GP IIb/IIIa antagonists have potential inhibitory effect on platelet aggregation, which are beneficial for acute thromboembolism T A B L E 5 The multiple logistics regression analysis of risk factors for MACE mediated by platelet. 35 Our results showed that infusion of platelet GP IIb/IIIa receptor blocker appeared to reduce platelet aggregation. The potential mechanism is that GP IIb/ III antagonist contributes to additional inhibitory effects on platelet aggregation mainly by reducing the expression of platelet phosphatidylserine and the cleavage of prothrombin. 36 In accordance with previous clinical studies, 15, 24 both CYP2C19*2 and *3 LOF alleles were highly associated with higher ADP-induced platelet aggregation for Chinese ACS patients medicated with clopidogrel. But in our study, CYP2C19*3 LOF alleles could not predict the risk of HPR compared with non-LOF alleles. One study showed that high risk of HPR was mainly attributed to CYP2C19*2 LOF alleles. 15 In contrast, a previous study showed that only CYP2C19*3 LOF alleles were independent risk factor of clopidogrel resistance for East Asian patients. 37 Based on the status quo, a larger sample size is necessary to further support the present study. The prevalence of CYP2C19*2 LOF alleles is high among East Asian patients. In this study, the results showed that CYP2C19*2 LOF alleles were associated with HPR compared with non-LOF alleles (RR: 1.21, 95% CI:1.05-1.39, P = 0.008). 38 A Korean prospective multicentre registered study reported that CYP2C19*2 LOF alleles in East Asian population were associated with higher platelet aggregation (adjusted OR 2.08, 95% CI 1.749-2.466, P < 0.0001). 39 This result could be explained by the mechanism that CYP2C19 is an indispensable drug metabolism enzyme catalysing the biotransformation of clopidogrel. CYP2C19*2 LOF alleles are associated with lower plasma level of the concentration of active metabolites of clopidogrel and diminished antiplatelet effect of clopidogrel. 33 Our results showed that CYP2C19*2 LOF alleles were associated with higher platelet activity for ACS patients (P < 0.05) as it increased platelet aggregation and thrombotic events. In our study, PON1 was another genetic factor affecting platelet activation. PON1, which is synthesized in the liver, plays an important part in biotransformation converting the pro-drug, clopidogrel, into its active metabolite. 40 One study reported that PON1 LOF alleles conferred higher risk of platelet aggregation [OR 3.64; 95% CI (1.21-10.92), P = 0.02]. 24 Our data indicate that it is necessary to adjust clopidogrel therapy for Chinese ACS patients with CYP2C19*2 and PON1 LOF alleles. Despite the role of ABCB1 on clopidogrel response, our study did not support that ABCB1 genotypes had a relevant impact on clopidogrel response. A previous study demonstrated that ABCB1 variants contributed to an increased risk of adverse cardiovascular events for Caucasians. 14 Dual antiplatelet therapy combining aspirin and P2Y12 receptor antagonist plays an important role in preventing thromboembolism events in post PCI patients. In our present study, CYP2C19*2 LOF alleles might be predictable factors for MACE, and a univariate analysis consistently showed that CYP2C19 metabolizers affected the occurrence of MACE in 1-year post PCI. Our data revealed that CYP2C19*2 LOF alleles were associated with a higher risk of MACE compared with non-LOF alleles [OR 2.571; 95% CI (1.143-5.780), P = 0.030]. Sun et al 29 reported that the risk of MACE in CYP2C19 metabolizers was 2.664 times higher than in noncarriers. Clopidogrel is activated by CYP2C19 and it then irreversibly inhibits the P2Y 12 subtype of ADP receptor. 12 Since clopidogrel could not be bio-transformed by the CYP2C19 LOF alleles, it could not effectively inhibit the active states of platelet and eventually, the thrombosis events would occur. Our study has some limitations as well: Firstly, it is a single cohort study with relatively small sample size, which to some extent weakens the reliability of our study. In future, large prospective, randomized, and well-controlled trials are needed to evaluate the association of clopidogrel polymorphism and antiplatelet effect. Secondly, long-term follow-up should be taken into consideration in future studies. In addition, though we obtained some MACE information via telephone, it could not fully demonstrate the functional recovery of patients, and a better and optimized follow-up scheme should be carried out in the future studies. Finally, we did not demonstrate the relationship between CYP2C19*17 and bleeding the limited sample size.
| CONCLUSION
For ACS patients implanted with drug-eluting stent, the presence of CYP2C19*2 and PON1 LOF alleles were the major drivers for HPR of clopidogrel. Moreover, CYP2C19*2 LOF alleles were associated with a higher risk LI ET AL.
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of MACE compared with non-LOF alleles. Clinical pharmacists can adjust the antiplatelet therapy for individuals based on their tested genetic results for clopidogrel metabolism to avoid the thromboembolism and bleeding events.
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